Cyberounds Logo
September 27, 2020 | LOGIN | REGISTER | HELP | 

email a friend print Bookmark and Share
Current and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis
CME credit is no longer available for this conference.
Aaron Miller, M.D..

Dr. Miller is Professor of Neurology and Medical Director Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY.

Within the past 12 months, Dr. Miller has received research support from Acorda, Novartis, Genentech, Genzyme, Sanofi-Avenits, Biogen Idec, Roche and Questor and been a consultant to Genzyme, Sanofi-Aventis, Biogen Idec, Glaxo Smith Kline, EMD Serono, Novartis, Accorda, Nuron Biotech, Accordant Health Services and Teva.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.

This activity is certified for neurology and primary care (internal medicine, family practice and women’s health) and for all health professionals interested in the treatment of RRMS.

This activity is made possible by an unrestricted educational grant from Biogen Idec.

Release Date: 06/02/2014
Termination Date: 06/01/2017

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Discuss the pathogenesis, epidemiology, symptoms and diagnosis of RRMS
  • Select and prescribe appropriate pharmaceuticals for patients with RRMS
  • Discuss the role of risk stratification (e.g., serum JC virus antibody status) in the therapeutic management of RRMS
  • Describe on-going clinical trials for emerging RRMS therapies/strategies and evaluate data on safety, efficacy and management of side effects.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity